RxDoctor Payments Data

Yuan-Fei Chang, MD

Family Medicine · City Of Industry, CANPI 1194739128

Payments from drug & device makers

$9,448in general payments, 2019–2025

Across 621 payments — averaging $15.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kowa Pharmaceuticals America, Inc.$2K
  • AstraZeneca$2K
  • Boehringer Ingelheim$1K
  • Amgen$532
  • Merck$438
  • Pfizer$406
  • plus $3K from 27 others

What the payments were for

  • Food & beverage$9,426100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,448 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$142,355
Medicare patients
439
Services billed
1,959

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin124$108,158
ProliaDenosumab31$52,897
JanuviaSitagliptin Phosphate59$47,142
VascepaIcosapent Ethyl85$39,313
FarxigaDapagliflozin Propanediol47$33,595
VemlidyTenofovir Alafenamide16$22,269
LivaloPitavastatin Calcium27$21,066
EliquisApixaban22$18,173
Atorvastatin Calcium1,321$16,733
JanumetSitagliptin Phos/Metformin Hcl21$16,311
Risedronate Sodium DrRisedronate Sodium58$15,837
Pitavastatin Calcium68$13,314
TradjentaLinagliptin16$11,945
Dexlansoprazole DrDexlansoprazole19$6,821
Rosuvastatin Calcium411$6,487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$1,256$120,102140 claims
MerckJanuvia, Janumet, Segluromet$438$65,62593 claims
AmgenProlia$532$52,89731 claims
AstraZenecaFarxiga$1,895$33,59547 claims
GileadVemlidy$16$22,26916 claims
Kowa Pharmaceuticals America, Inc.Livalo$1,992$21,06627 claims
PfizerEliquis$406$18,17322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in City Of Industry

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →